Core Insights - Cartesian Therapeutics is advancing its lead cell therapy candidate, Descartes-08, for autoimmune diseases, with significant progress in clinical trials and strategic priorities for 2026 [1][2][9] Group 1: Clinical Trials and Developments - Enrollment is on track for the Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG), which is designed to assess the therapy against a placebo in approximately 100 participants [3] - The Phase 2 trial for myositis is set to begin in the first half of 2026, with a seamless adaptive design allowing for a potential single pivotal trial after an interim analysis [2][3] - A Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis has been initiated, with the therapy previously granted Rare Pediatric Disease Designation by the FDA [4][8] Group 2: Mechanism of Action and Efficacy - Descartes-08 targets B-cell maturation antigen (BCMA) and has shown deep and durable responses in MG patients, with 57% of participants achieving minimal symptom expression by Month 6 and maintaining it through Month 12 [5] - The therapy has demonstrated a favorable safety profile, with no instances of cytokine release syndrome or neurotoxicity reported, supporting its outpatient administration [5][8] Group 3: Financial Outlook - The company expects its current cash resources to support operations, including the ongoing Phase 3 trial and the initiation of the Phase 2 myositis trial, through mid-2027 [7] Group 4: Strategic Initiatives - Cartesian is exploring enhanced delivery platforms for its cell therapies, including agreements to optimize in-vivo delivery of Descartes-08 and next-generation agents [6] - The appointment of Adrian Bot, M.D., Ph.D., to the Board of Directors is aimed at supporting the strategic expansion of the company's cell therapy initiatives [6]

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Presentation: Tuesday, January 13, 2026 at 10:30am – 11:10 am PTLocation: The Westin St. Francis, Georgian Room A live webcast and archived replay of the presentation will be available on the Company’s web ...

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accredited healthcare specialist investors in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $150 million, b ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Ganzhou Hemay Pharmaceutical Co., Ltd. 贛州和美藥業股份有限公司 (A joint stock company incorporated in the People's Republic of ...

Core Insights - Vor Bio has reported significant progress in its late-stage clinical programs for telitacicept, a dual BAFF/APRIL inhibitor, demonstrating consistent efficacy and safety across multiple autoimmune diseases [2][3][4] Clinical Developments - Telitacicept has shown promising results in generalized myasthenia gravis (gMG), with 96.2% of patients achieving a ≥ 3-point improvement in MG-ADL after 48 weeks [6] - In Sjögren's disease, telitacicept met primary and secondary endpoints, with 67.1% of patients achieving a modified SRI-4 response at Week 52 compared to 32.7% on placebo [6] - The treatment for systemic lupus erythematosus (SLE) has been reinforced as a potential disease-modifying therapy, with significant reductions in proteinuria and stabilization of kidney function [11][5] Financial Overview - Vor Bio raised expected gross proceeds of $115 million from a public offering in November 2025, which will support operations into the second quarter of 2027 [1][13] - The company reported a net loss of $812.7 million for Q3 2025, primarily due to a loss on change in fair value of outstanding liability-classified warrants [13][15] Leadership and Governance - Vor Bio has expanded its leadership team and board to enhance its global development capabilities, with several key appointments made in 2025 [9][12] Cash Position - As of September 30, 2025, Vor Bio had cash, cash equivalents, and marketable securities totaling $170.5 million, which is expected to fund ongoing operations [13][14]

Core Insights - Zenas BioPharma reported significant advancements in its clinical trials, particularly with obexelimab, which showed promising results in treating autoimmune diseases [1][2][3] - The company has secured substantial funding to support its clinical development and commercialization efforts, including a $300 million agreement with Royalty Pharma [1][6] - Zenas is expanding its product pipeline with the acquisition of three new autoimmune product candidates, including orelabrutinib, which is in Phase 3 development for multiple sclerosis [1][3][10] Clinical Trial Updates - The Phase 3 INDIGO trial for obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) is set to report topline results around year-end 2025, marking it as the largest clinical trial for this condition to date [1][3] - The Phase 2 MoonStone trial for obexelimab in Relapsing Multiple Sclerosis (RMS) demonstrated a 95% relative reduction in new gadolinium-enhancing lesions compared to placebo, with a p-value of 0.0009 [3][4] - Zenas expects to report 24-week data from the MoonStone trial in the first quarter of 2026 [3] Financial Highlights - As of September 30, 2025, Zenas had cash, cash equivalents, and investments totaling $301.6 million, which, along with recent financing, is expected to fund operations into the fourth quarter of 2026 [7][18] - The company reported a net loss of $51.5 million for the third quarter of 2025, compared to a net loss of $38.6 million for the same period in 2024 [13][17] - Research and development expenses for the quarter were $34.4 million, while general and administrative expenses increased to $13.2 million from $7.5 million year-over-year [7][17] Pipeline Expansion - Zenas has entered into a license agreement for orelabrutinib, a BTK inhibitor, granting global development and commercialization rights outside Greater China and Southeast Asia [3][10] - The company is also advancing two additional product candidates, ZB021 and ZB022, both of which are expected to enter Phase 1 clinical development in 2026 [4][10] Company Overview - Zenas BioPharma is focused on developing transformative therapies for autoimmune diseases, with a strategy that includes acquiring and developing product candidates that offer superior clinical benefits [11] - The company aims to become a leader in the biopharmaceutical industry, leveraging its experienced leadership and disciplined approach to product development [11]

Core Insights - Nkarta, Inc. has reported significant progress in its NKX019 clinical program aimed at treating autoimmune diseases, marking a key milestone in its development efforts [2][4] - The company has streamlined patient enrollment in its Ntrust-1 and Ntrust-2 clinical trials, enhancing efficiency and safety profile consistency for NKX019 [2][6][7] - Financially, Nkarta maintains a strong cash position of $316.5 million as of September 30, 2025, which is projected to fund operations into 2029 [6][9] Clinical Program Developments - Enrollment is currently underway in the second dose-escalation cohort, with complete B-cell depletion observed in all patients treated with NKX019 using a modified lymphodepletion regimen [6][3] - The FDA has approved protocol amendments that allow for simultaneous dosing of multiple participants, expediting the trial process [7][3] - Initial data from the NKX019 trials in multiple autoimmune indications is expected to be presented at a medical conference in 2026 [6][10] Financial Highlights - For the third quarter of 2025, Nkarta reported a net loss of $21.7 million, or $0.29 per share, which includes non-cash charges primarily related to share-based compensation [8][21] - Research and development expenses for the third quarter were $20.2 million, while general and administrative expenses were $7.1 million [7][21] - The total operating expenses for the third quarter amounted to $27.3 million, compared to $33.8 million in the same quarter of the previous year [21] Balance Sheet Overview - As of September 30, 2025, Nkarta's total assets were valued at $427.2 million, with liabilities amounting to $89.3 million [23] - The company's cash, cash equivalents, restricted cash, and investments decreased from $380.5 million at the end of 2024 to $316.5 million [23]

Core Insights - Takeda has presented new data indicating that mezagitamab (TAK-079) shows sustained effects on kidney function in patients with primary IgA nephropathy, maintaining stable kidney function (eGFR) 18 months after the last treatment dose [1][2][4] Group 1: Clinical Study Results - In a Phase 1b open-label study, kidney function remained stable in patients with IgA nephropathy through Week 96, with a mean change in eGFR from baseline of +2.5 (95% CI: 1.8, +7.6; n=12) [4] - Patients experienced a 55.2% mean reduction in proteinuria (95% CI: 30.2, 72.6; n=13) and a 50.1% reduction in Gd-IgA1 levels by Week 96 [4][5] - Hematuria resolved in 60% of patients by Week 96, indicating significant improvements in kidney health [4] Group 2: Safety and Tolerability - Mezagitamab was generally well tolerated, with no serious adverse events, including serious hypersensitivity or injection-related reactions reported [5][6] - The study did not identify any new safety concerns, reinforcing the potential of mezagitamab as a treatment for autoimmune diseases like IgA nephropathy [5] Group 3: Future Development and Designations - Takeda is currently conducting pivotal Phase 3 clinical trials for mezagitamab in both primary IgA nephropathy and chronic immune thrombocytopenia, with patient enrollment ongoing [6] - Mezagitamab received Orphan Drug Designation from the European Medicines Agency for primary IgA nephropathy and Breakthrough Therapy Designation from the U.S. FDA for chronic immune thrombocytopenia [6]

Core Insights - Cartesian Therapeutics is making significant progress in its clinical trials, particularly the Phase 3 AURORA trial of Descartes-08 for myasthenia gravis (MG) and anticipates preliminary data from the Phase 2 trial in systemic lupus erythematosus (SLE) by the end of the year [2][5][6] Financial Overview - As of September 30, 2025, the company reported cash, cash equivalents, and restricted cash totaling approximately $145.1 million, which is expected to support operations into mid-2027 [4][10] - The net loss for the third quarter of 2025 was $35.9 million, or $1.38 per share, compared to a net loss of $24.2 million, or $1.13 per share, for the same period in 2024 [10][16] Clinical Development Updates - The Phase 3 AURORA trial is a randomized, double-blind, placebo-controlled study assessing Descartes-08, targeting approximately 100 participants with AChR Ab+ MG, with a primary endpoint focused on improvement in MG Activities of Daily Living (MG-ADL) score [5][6] - The company plans to initiate a Phase 2 pediatric basket trial targeting juvenile autoimmune diseases, including juvenile SLE and juvenile MG, by the end of the year [5][6] Pipeline Progress - Descartes-08 is designed to be administered without preconditioning chemotherapy and has received Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation from the FDA for MG [6][8] - Descartes-15, a next-generation CAR-T therapy, is currently in a Phase 1 trial for multiple myeloma, showing promising preclinical results [7][8]

Core Insights - Dianthus Therapeutics reported significant advancements in the clinical development of claseprubart, particularly in the Phase 2 MaGic trial for generalized Myasthenia Gravis (gMG), showing statistically significant improvements in MG-ADL and QMG scores at Week 13 [1][4][5] - The company has accelerated the timeline for the interim responder analysis of the Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to Q2 2026 due to faster enrollment [1][6] - An exclusive licensing agreement for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor, was announced, with Phase 1 data expected in 2H 2026 [1][8][12] - Dianthus has an estimated cash position of approximately $525 million, providing financial runway into 2028 [1][18] Clinical Development Updates - Claseprubart demonstrated rapid and clinically meaningful improvements in gMG patients, with the 300mg/2mL Q2W dose showing significant efficacy across multiple endpoints [4][5] - The Phase 3 trial for claseprubart in gMG is anticipated to begin in 2026, with a focus on both 300mg/2mL Q2W and Q4W dosing [1][11] - The ongoing Phase 2 MoMeNtum trial for Multifocal Motor Neuropathy (MMN) is expected to yield top-line results in 2H 2026 [1][7] Financial Performance - For Q3 2025, Dianthus reported a net loss of $36.8 million, or $0.97 per share, compared to a net loss of $25.2 million, or $0.74 per share, in Q3 2024 [10][24] - Research and development expenses increased to $32.5 million in Q3 2025, driven by higher clinical costs and increased headcount [10][18] - General and administrative expenses rose to $8.2 million in Q3 2025, reflecting increased staffing [10][18] Corporate Strategy - The company aims to establish itself as a leader in the autoimmune disease treatment space, focusing on delivering best-in-class therapies with infrequent, subcutaneous self-administration [2][3] - The CEO emphasized the importance of executing their plans to advance both claseprubart and DNTH212 as transformative therapies for severe autoimmune diseases [2][3]